The DOI matches its Crossref record; 227 of the 227 references it cites were found in a registry or an index.
DNA Vaccines—How Far From Clinical Use?
Open accessAbstract
Two decades ago successful transfection of antigen presenting cells (APC) in vivo was demonstrated which resulted in the induction of primary adaptive immune responses. Due to the good biocompatibility of plasmid DNA, their cost-efficient production and long shelf life, many researchers aimed to develop DNA vaccine-based immunotherapeutic strategies for treatment of infections and cancer, but also autoimmune diseases and allergies. This review aims to summarize our current knowledge on the course of action of DNA vaccines, and which factors are responsible for the poor immunogenicity in human so far. Important optimization steps that improve DNA transfection efficiency comprise the introduction of DNA-complexing nano-carriers aimed to prevent extracellular DNA degradation, enabling APC targeting, and enhanced endo/lysosomal escape of DNA. Attachment of virus-derived nuclear localization sequences facilitates nuclear entry of DNA. Improvements in DNA vaccine design include the use of APC-specific promotors for transcriptional targeting, the arrangement of multiple antigen sequences, the co-delivery of molecular adjuvants to prevent tolerance induction, and strategies to circumvent potential inhibitory effects of the vector backbone. Successful clinical use of DNA vaccines may require combined employment of all of these parameters, and combination treatment with additional drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–227 of 227
Trial watch: DNA-based vaccines for oncological indications
Pierini, S., Perales-Linares, R. F., Uribe‐Herranz, M., Pol, J. G., Zitvogel, L., Kroemer, G., Facciabene, A., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1398878 · Cited by 30
Bogacheva, M. S., Egorova, A., Slita, A., Maretina, M. A., Баранов, В. С., & Kiselev, A. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.10.001 · Cited by 27
Ghassami, E., Varshosaz, J., & Taymouri, S. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180813114841 · Cited by 27
Grubor‐Bauk, B., Yu, W., Wijesundara, D. K., Gummow, J., Garrod, T. J., Brennan, A. J., Voskoboinik, I., & Gowans, E. J. (2015) · Gene Therapy · doi:10.1038/gt.2015.86 · Cited by 26
Kumari, M., Liu, C., & Wu, W. (2017) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2017.11.013 · Cited by 26
Larsen, K. C., Spencer, A. J., Goodman, A. L., Gilchrist, A., Furze, J. M., Rollier, C. S., Kiss‐Toth, E., Gilbert, S. C., Bregu, M., Soilleux, E. J., et al. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.07.025 · Cited by 25
Mével, M., Haudebourg, T., Colombani, T., et al. (2015) · The Journal of Gene Medicine · doi:10.1002/jgm.2869 · Cited by 24
DNA immunization using a non-viral promoter
Vanniasinkam, T., Reddy, S. T., & Ertl, H. C. J. (2005) · Virology · doi:10.1016/j.virol.2005.08.040 · Cited by 24
Thomas, S. K., Cha, S.-C., Smith, D. L., Kim, K. H., Parshottam, S. R., Rao, S. S., Popescu, M. S., Lee, V. Y., Neelapu, S. S., & Kwak, L. W. (2018) · BMC Cancer · doi:10.1186/s12885-018-4094-2 · Cited by 23
Driving Gene Expression Specifically in Dendritic Cells
Brocker, T., Riedinger, M., & Karjalainen, K. (1997) · Advances in experimental medicine and biology · doi:10.1007/978-1-4757-9966-8_9 · Cited by 22
Interplay of Promoter Usage and Intragenic CpG Content: Impact on GFP Reporter Gene Expression
Krinner, S., Heitzer, A. P., Asbach, B., & Wagner, R. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.075 · Cited by 22
Tyrosine residues play an important role in heme detoxification by serum albumin
Huang, Y., Shuai, Y., Li, H., & Gao, Z. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.11.011 · Cited by 22
Garg, R., Kaur, M., Saxena, A., Prasad, R., & Bhatnagar, R. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.02.011 · Cited by 22
Multiple Approaches for Increasing the Immunogenicity of an Epitope-Based Anti-HIV Vaccine
Rosa, D. S., Ribeiro, S. P., Fonseca, S. G., Almeida, R. R., Santana, V. C., Apostólico, J. D. S., Kalil, J. E., & Cunha‐Neto, E. (2015) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2015.0101 · Cited by 21
Carbon Dioxide-Generating PLG Nanoparticles for Controlled Anti-Cancer Drug Delivery
Jang, H. J., Jeong, E. J., & Lee, K. Y. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2359-8 · Cited by 21
Targeting dendritic cells with antigen via dendritic cell-associated promoters
Moulin, V., Morgan, M. E., Eleveld-Trancikova, D., Haanen, J. B. A. G., Wielders, E., Looman, M. W. G., Janssen, R. A. J., Figdor, C. G., Jansen, B., & Adema, G. J. (2012) · Cancer Gene Therapy · doi:10.1038/cgt.2012.2 · Cited by 20
Mottais, A., Gall, T. L., Sibiril, Y., Ravel, J., Laurent, V., d’Arbonneau, F., & Montier, T. (2017) · Bioscience Reports · doi:10.1042/bsr20160618 · Cited by 20
Luo, M., Qu, X., Pan, R., Zhu, D., Zhang, Y., Wu, J., & Pan, Z. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.01.060 · Cited by 19
Effective antitumor peptide vaccines can induce severe autoimmune pathology
Sultan, H., Trillo-Tinoco, J., Rodríguez, P. C., & Celis, E. (2017) · Oncotarget · doi:10.18632/oncotarget.19688 · Cited by 15
Shedlock, D. J., Tingey, C., Mahadevan, L., Hutnick, N. A., Reuschel, E. L., Kudchodkar, S. B., Flingai, S., Yan, J. J., Kim, J., Ugen, K. E., et al. (2014) · Vaccines · doi:10.3390/vaccines2020196 · Cited by 13
Transcriptional Control of Dendritic Cell Differentiation
Sasaki, I., & Kaisho, T. (2014) · Current topics in microbiology and immunology · doi:10.1007/82_2014_378 · Cited by 10
Chen, B.-Y., Zhou, G., Li, Q.-L., Lu, J., Shi, D.-Y., Pang, X., Zhou, X., Yu, Y., & Huang, P. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.08.004 · Cited by 10
Efficacy Testing of H56 cDNA Tattoo Immunization against Tuberculosis in a Mouse Model
Platteel, A. C. M., Nieuwenhuizen, N. E., Domaszewska, T., Schuerer, S., Zedler, U., Brinkmann, V., Sijts, A. J. A. M., & Kaufmann, S. H. E. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01744 · Cited by 10
Investigating Tick-borne Flaviviral-like Particles as a Delivery System for Gene Therapy
Neddermeyer, A., Hultenby, K. R., Paidikondala, M., Schuchman, R. M., & Bidokhti, M. R. M. (2017) · Current Therapeutic Research · doi:10.1016/j.curtheres.2017.10.003 · Cited by 8
Castor, T., Yogev, N., Blank, T., Barwig, C., Prinz, M., Waisman, A., Bros, M., & Reske‐Kunz, A. B. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191927 · Cited by 8
Self-citationSun, L. J., Yuan, Q., Xu, T., Yao, L., Feng, J., Ma, J., Wang, L., Lv, C., & Wang, D. (2017) · Biotechnology Letters · doi:10.1007/s10529-017-2342-1 · Cited by 5
Vargas, J. E., Salton, G. D., Laino, A. S., Pires, T. D., Bonamino, M., Lenz, G., & Cañedo, A. D. (2012) · Plasmid · doi:10.1016/j.plasmid.2012.06.001 · Cited by 4
Cited by
Immunological considerations for COVID-19 vaccine strategies
Jeyanathan, M., Afkhami, S., Smaill, F., Miller, M. S., Lichty, B. D., & Xing, Z. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-00434-6 · Cited by 1,015
COVID-19 Vaccine: A comprehensive status report
Kaur, S. P., & Gupta, V. (2020) · Virus Research · doi:10.1016/j.virusres.2020.198114 · Cited by 852
SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates
Kyriakidis, N. C., López-Cortés, A., González, E. V., Grimaldos, A. B., & Prado, E. O. (2021) · npj Vaccines · doi:10.1038/s41541-021-00292-w · Cited by 698
A systematic review of SARS-CoV-2 vaccine candidates
Dong, Y., Dai, T., Wei, Y., Zhang, L., Zheng, M., & Zhou, F. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00352-y · Cited by 545
Self-amplifying RNA vaccines for infectious diseases
Bloom, K., van den Berg, F., & Arbuthnot, P. (2021) · Gene Therapy · doi:10.1038/s41434-020-00204-y · Cited by 487
Metadata
- Authors
- Hobernik, D., & Bros, M.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-11-15
- Volume
- 19
- Issue
- 11
- Pages
- 3605
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2900898034
- Cited by
- 457
- References
- 227
- FWCI
- 18.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.